Arcus Biosciences develops investigational cancer medicines for patients and the doctors who treat them. It last closed at $15.62 on Nov 20, down 1.01% on the day. The next earnings report for RCUS is expected around Wed, Feb 24, 2027, after the close. For the quarter ended Sep 2026, RCUS reported EPS of -$1.00 on revenue of $9.0M, with revenue down 65.4% from a year ago. Over its last 8 reports the stock moved an average of 3.7% the session after earnings. Over the last 12 months RCUS insiders bought $0 of stock on the open market and sold $9.5M, according to SEC Form 4 filings.
AI Auto Pilots
Is RCUS in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold RCUS.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on RCUSStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
RCUS · as of the Nov 20 close · updated each morning
Downtrend, oversold
The stock is 14% below its 20 day and 37% below its 50 day average. It is 56% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 29), oversold. The nearest support is the 52 week low at $15.56, and the nearest resistance the Pivot at $15.95.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 7.2%/day
Key levels
$31.7352 week high+103.1%
$25.19100 day average+61.3%
$24.34200 day average+55.8%
$21.4750 day average+37.5%
$19.02Swing high (Oct 29)+21.8%
$17.7620 day average+13.7%
$16.33Pivot R1+4.5%
$15.95Pivot+2.1%
$15.62Last close
$15.5652 week low−0.4%
$15.23Pivot S1−2.5%
Indicators
RSI (14)
28.58
Oversold below 30
Oversold
MACD
-1.58
Below its signal line
Bearish
Stochastic
1.7
Near the bottom of its range
Oversold
ADX (14)
33.3
Trending down
Williams %R
-98.5
Oversold below −80, overbought above −20
Oversold
CCI (20)
-159.6
Oversold below −100, overbought above 100
Oversold
Rate of change
−14.6%
Change over 10 sessions
Bearish
ATR (14)
$1.12
Typical daily range, 7.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Pullback inside a longer uptrend, oversold
Short trendBearish
Long trendBullish
MomentumWeak
StretchOversold
VolatilityNormal, 18.9%/day
Key levels
$31.7352 week high+103.1%
$25.19100 day average+61.3%
$24.34200 day average+55.8%
$21.4750 day average+37.5%
$19.02Swing high (Oct 29)+21.8%
$17.7620 day average+13.7%
$16.33Pivot R1+4.5%
$15.95Pivot+2.1%
$15.62Last close
$15.5652 week low−0.4%
$15.23Pivot S1−2.5%
Indicators
RSI (14)
27.39
Oversold below 30
Oversold
MACD
-1.99
Below its signal line
Bearish
Stochastic
3.0
Near the bottom of its range
Oversold
ADX (14)
26.5
Trending down
Williams %R
-99.6
Oversold below −80, overbought above −20
Oversold
CCI (20)
-155.1
Oversold below −100, overbought above 100
Oversold
Rate of change
−36.5%
Change over 10 sessions
Bearish
ATR (14)
$2.96
Typical daily range, 18.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for RCUS
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how RCUS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow RCUS usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for RCUSHow many large options trades hit RCUS, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in RCUS in the last 90 days.
From SEC Form 4 filings by RCUS's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RCUS is in one of them and how their past RCUS trades turned out.
Arcus Biosciences is a biopharmaceutical company based in Hayward, California. It develops investigational medicines, mainly for cancer, and tests them in clinical trials carried out with contract research organizations and trial sites. Its products are still investigational, and it works with partners such as AstraZeneca, Gilead and Taiho on some of its programs. Its intended users are cancer patients and the doctors who treat them.